Theriva Biologics, Inc. (TOVX) stock
Close on Nov 11, 2026Market cap $7.38MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $7.38M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -226.22%
Fundamentals
- EPS, diluted
- -$2.08
- Free cash flow
- -$16.70M
- Diluted shares
- 46M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $0.15
- Open
- $0.16
- Day's range
- $0.15 – $0.17
- Volume
- 654,452
- Average volume (20 days)
- 5,238,011
- Beta (5 years)
- 1.31
- 52-week range
- $0.14 – $0.49
- RSI (14 days)
- 33.4
- Volatility (1 year)
- 112.1%
- Relative volume
- 0.33×
- WACC
- 11.4%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TOVX | S&P 500 | Difference | TOVX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.9% | -2.4% | −23.4 pts | ||
| 3 months | -30.0% | -1.2% | −28.9 pts | ||
| Year to date | -23.5% | +12.3% | −35.8 pts | ||
| 1 year | -41.7% | +12.4% | −54.1 pts | ||
| 3 years | -98.6% | +78.8% | −177.4 pts | -76.1% | +21.4% |
| 5 years | -99.8% | +75.2% | −175.0 pts | -72.4% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -67.9% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Theriva Biologics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Update
- Update
- Results
About Theriva Biologics
Pharmaceutical Preparations
Theriva Biologics, S.L. (operating as an oncology-focused biopharmaceutical business) develops clinical-stage therapeutics to treat solid tumors and related conditions with high unmet medical need. The business concentrates on an oncolytic adenovirus platform engineered to induce tumor cell death, break down tumor stroma via the expression of PH20 hyaluronidase, and stimulate anti-tumor immune responses. Its lead clinical candidate, VCN-01, undergoes evaluation for indications including unresectable metastatic pancreatic ductal adenocarcinoma, pediatric retinoblastoma, and head and neck squamous cell carcinoma, administered either alone or alongside standard-of-care chemotherapy and immunotherapy regimens. The enterprise previously advanced gastrointestinal programs, including SYN-004 and the licensed asset SYN-020.
Company profile, executives and historyTheriva Biologics stock: common questions
What is Theriva Biologics's stock price?
TOVX closed at $0.16 on Nov 11, 2026, up 4.35% on the day. Over the past 52 weeks it traded between $0.14 and $0.49.
What is Theriva Biologics's market cap?
Theriva Biologics was worth $7.38M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TOVX's P/E ratio?
Theriva Biologics lost money over fiscal 2025 (diluted EPS -$2.08), so it has no meaningful P/E ratio.
Does Theriva Biologics pay a dividend?
No. Theriva Biologics has not paid a cash dividend over the last twelve months.
When does Theriva Biologics report earnings next?
Theriva Biologics is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TOVX stock performed over the past year?
Including dividends, TOVX returned -41.7% over the past year, against +12.4% for the S&P 500.
How many TOVX shares are sold short?
1M shares were sold short at the latest FINRA report, 3.11% of the float, or 2.7 days of average trading volume.
Who are Theriva Biologics's competitors?
Companies most similar to Theriva Biologics by business, industry and size include PYXS, ONCY, RNAZ, OSTX, CBIO.
See a number that looks wrong?